Shares of Check Cap Ltd (NASDAQ:CHEK) have received an average broker rating score of 1.50 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company.
Brokerages have set a 12-month consensus price objective of $10.00 for the company and are expecting that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 63 out of 255 based on the ratings given to its competitors.
CHEK has been the topic of several analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Check Cap in a research report on Tuesday, December 31st. Zacks Investment Research upgraded Check Cap from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. Finally, Dawson James initiated coverage on Check Cap in a research report on Thursday, December 5th. They set a “buy” rating and a $4.00 price target on the stock.
CHEK opened at $1.56 on Monday. Check Cap has a 12 month low of $1.28 and a 12 month high of $3.50. The stock’s 50 day moving average price is $1.91 and its 200 day moving average price is $1.81.
About Check Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Further Reading: Do You Need a Fiduciary?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.